 Scott Demarest
Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spasms, Infantile | 40 | 2025 | 136 | 12.060 |
Why?
| | Epileptic Syndromes | 36 | 2025 | 96 | 10.640 |
Why?
| | Epilepsy | 22 | 2025 | 386 | 5.680 |
Why?
| | Vision Disorders | 8 | 2025 | 179 | 2.350 |
Why?
| | Precision Medicine | 6 | 2024 | 454 | 1.760 |
Why?
| | Neurodevelopmental Disorders | 5 | 2026 | 223 | 1.630 |
Why?
| | Psychometrics | 8 | 2025 | 731 | 1.370 |
Why?
| | Anticonvulsants | 9 | 2023 | 242 | 1.360 |
Why?
| | Seizures | 15 | 2025 | 473 | 1.360 |
Why?
| | Genetic Testing | 5 | 2023 | 480 | 1.330 |
Why?
| | Developmental Disabilities | 4 | 2026 | 279 | 1.280 |
Why?
| | Gene Editing | 2 | 2021 | 91 | 1.170 |
Why?
| | Chromosomes, Human, Pair 8 | 2 | 2025 | 38 | 1.130 |
Why?
| | Child, Preschool | 30 | 2026 | 11789 | 1.050 |
Why?
| | Pregnanolone | 3 | 2024 | 34 | 1.010 |
Why?
| | Communication | 5 | 2025 | 972 | 1.000 |
Why?
| | Child | 42 | 2026 | 22599 | 1.000 |
Why?
| | Infant | 24 | 2025 | 10022 | 0.940 |
Why?
| | Caregivers | 6 | 2026 | 1062 | 0.940 |
Why?
| | Genetic Therapy | 3 | 2024 | 313 | 0.920 |
Why?
| | Epilepsy, Tonic-Clonic | 1 | 2023 | 6 | 0.820 |
Why?
| | Epilepsies, Myoclonic | 3 | 2020 | 59 | 0.820 |
Why?
| | Electroencephalography | 11 | 2025 | 551 | 0.730 |
Why?
| | Disorders of Excessive Somnolence | 1 | 2022 | 38 | 0.710 |
Why?
| | Severity of Illness Index | 4 | 2025 | 2922 | 0.700 |
Why?
| | Gain of Function Mutation | 1 | 2021 | 34 | 0.690 |
Why?
| | Long QT Syndrome | 1 | 2022 | 69 | 0.690 |
Why?
| | Haploinsufficiency | 1 | 2021 | 54 | 0.690 |
Why?
| | Adolescent | 25 | 2026 | 22405 | 0.680 |
Why?
| | Quality of Life | 10 | 2026 | 3183 | 0.640 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 259 | 0.640 |
Why?
| | Humans | 66 | 2026 | 144665 | 0.610 |
Why?
| | Parents | 6 | 2025 | 1395 | 0.600 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2022 | 194 | 0.580 |
Why?
| | Sleep Wake Disorders | 2 | 2024 | 308 | 0.580 |
Why?
| | Brain Waves | 1 | 2018 | 45 | 0.540 |
Why?
| | Symptom Assessment | 1 | 2019 | 136 | 0.530 |
Why?
| | Clinical Trials as Topic | 4 | 2024 | 1056 | 0.490 |
Why?
| | Surveys and Questionnaires | 10 | 2025 | 6041 | 0.490 |
Why?
| | Reproducibility of Results | 10 | 2025 | 3414 | 0.470 |
Why?
| | Male | 34 | 2026 | 72425 | 0.470 |
Why?
| | Physicians | 1 | 2024 | 949 | 0.450 |
Why?
| | Female | 34 | 2026 | 78301 | 0.440 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 552 | 0.440 |
Why?
| | Chromosome Disorders | 2 | 2026 | 45 | 0.440 |
Why?
| | MELAS Syndrome | 1 | 2014 | 5 | 0.430 |
Why?
| | Genetic Predisposition to Disease | 1 | 2023 | 2350 | 0.420 |
Why?
| | Genetic Association Studies | 3 | 2020 | 369 | 0.400 |
Why?
| | DNA, Mitochondrial | 1 | 2014 | 212 | 0.380 |
Why?
| | Movement Disorders | 3 | 2023 | 70 | 0.360 |
Why?
| | Double-Blind Method | 4 | 2024 | 2033 | 0.350 |
Why?
| | Age of Onset | 3 | 2025 | 551 | 0.340 |
Why?
| | Adrenocorticotropic Hormone | 3 | 2023 | 147 | 0.340 |
Why?
| | Lennox Gastaut Syndrome | 2 | 2021 | 19 | 0.300 |
Why?
| | Cohort Studies | 5 | 2021 | 5957 | 0.300 |
Why?
| | Adult | 17 | 2026 | 40486 | 0.300 |
Why?
| | Young Adult | 12 | 2026 | 14119 | 0.290 |
Why?
| | Communication Disorders | 2 | 2025 | 13 | 0.280 |
Why?
| | Rett Syndrome | 3 | 2024 | 41 | 0.280 |
Why?
| | Phenotype | 7 | 2024 | 3147 | 0.280 |
Why?
| | Retrospective Studies | 7 | 2025 | 17147 | 0.250 |
Why?
| | Treatment Outcome | 7 | 2024 | 11734 | 0.240 |
Why?
| | Mutation | 5 | 2021 | 4081 | 0.240 |
Why?
| | Catatonia | 1 | 2026 | 13 | 0.230 |
Why?
| | Brain | 2 | 2014 | 2933 | 0.220 |
Why?
| | Genetic Diseases, Inborn | 1 | 2024 | 44 | 0.210 |
Why?
| | Infant, Newborn | 4 | 2024 | 6399 | 0.210 |
Why?
| | 5' Untranslated Regions | 1 | 2024 | 59 | 0.210 |
Why?
| | Disability Evaluation | 1 | 2025 | 310 | 0.200 |
Why?
| | Psychotic Disorders | 1 | 2026 | 185 | 0.200 |
Why?
| | Status Epilepticus | 1 | 2023 | 67 | 0.190 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2023 | 122 | 0.190 |
Why?
| | Sex Factors | 2 | 2019 | 2104 | 0.180 |
Why?
| | Brain Diseases | 1 | 2023 | 152 | 0.180 |
Why?
| | Vigabatrin | 2 | 2023 | 19 | 0.180 |
Why?
| | Child Behavior | 1 | 2024 | 236 | 0.180 |
Why?
| | Checklist | 1 | 2023 | 111 | 0.180 |
Why?
| | Vagus Nerve Stimulation | 2 | 2019 | 28 | 0.170 |
Why?
| | Neurologists | 1 | 2021 | 23 | 0.170 |
Why?
| | Piperidines | 1 | 2023 | 219 | 0.170 |
Why?
| | Oligonucleotides, Antisense | 1 | 2021 | 117 | 0.170 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5869 | 0.160 |
Why?
| | Intellectual Disability | 1 | 2022 | 174 | 0.160 |
Why?
| | Infusions, Intraventricular | 1 | 2020 | 4 | 0.160 |
Why?
| | Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2020 | 6 | 0.160 |
Why?
| | Neuronal Ceroid-Lipofuscinoses | 1 | 2020 | 5 | 0.160 |
Why?
| | Aminopeptidases | 1 | 2020 | 21 | 0.160 |
Why?
| | Infusion Pumps | 1 | 2020 | 33 | 0.160 |
Why?
| | Leukoencephalopathies | 1 | 2020 | 24 | 0.160 |
Why?
| | Serine Proteases | 1 | 2020 | 26 | 0.160 |
Why?
| | Drug Therapy, Combination | 1 | 2023 | 1044 | 0.160 |
Why?
| | Hemiplegia | 1 | 2019 | 20 | 0.150 |
Why?
| | Dystonic Disorders | 1 | 2019 | 27 | 0.150 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2019 | 54 | 0.150 |
Why?
| | DNA Polymerase gamma | 1 | 2019 | 8 | 0.150 |
Why?
| | Speech Disorders | 1 | 2019 | 29 | 0.150 |
Why?
| | Electrocardiography | 1 | 2022 | 664 | 0.150 |
Why?
| | Spasm | 3 | 2023 | 21 | 0.150 |
Why?
| | NAV1.1 Voltage-Gated Sodium Channel | 1 | 2019 | 22 | 0.140 |
Why?
| | Autonomic Nervous System Diseases | 1 | 2019 | 36 | 0.140 |
Why?
| | Neural Cell Adhesion Molecules | 1 | 2019 | 38 | 0.140 |
Why?
| | Cell Adhesion Molecules, Neuronal | 1 | 2019 | 42 | 0.140 |
Why?
| | Glucose Transporter Type 1 | 1 | 2019 | 49 | 0.140 |
Why?
| | Disease Management | 2 | 2024 | 650 | 0.140 |
Why?
| | Pyridines | 1 | 2023 | 603 | 0.140 |
Why?
| | Neurosurgical Procedures | 1 | 2020 | 202 | 0.140 |
Why?
| | Preexisting Condition Coverage | 1 | 2017 | 2 | 0.130 |
Why?
| | Family Health | 1 | 2019 | 191 | 0.130 |
Why?
| | Cognition Disorders | 2 | 2019 | 539 | 0.130 |
Why?
| | Receptors, GABA-A | 1 | 2019 | 137 | 0.130 |
Why?
| | Prednisolone | 1 | 2017 | 66 | 0.130 |
Why?
| | Calcium-Binding Proteins | 1 | 2019 | 222 | 0.130 |
Why?
| | Delphi Technique | 1 | 2019 | 330 | 0.130 |
Why?
| | Pilot Projects | 1 | 2023 | 1886 | 0.130 |
Why?
| | Sequence Analysis, DNA | 1 | 2020 | 828 | 0.130 |
Why?
| | Family | 1 | 2022 | 685 | 0.130 |
Why?
| | Recombinant Proteins | 1 | 2020 | 1363 | 0.120 |
Why?
| | Drug Resistant Epilepsy | 1 | 2018 | 136 | 0.120 |
Why?
| | Genomics | 1 | 2021 | 831 | 0.120 |
Why?
| | Health Surveys | 1 | 2018 | 517 | 0.120 |
Why?
| | Nerve Tissue Proteins | 1 | 2019 | 590 | 0.110 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2014 | 31 | 0.110 |
Why?
| | Nervous System Malformations | 1 | 2014 | 46 | 0.100 |
Why?
| | Patient Care Team | 1 | 2020 | 690 | 0.100 |
Why?
| | Follow-Up Studies | 1 | 2023 | 5414 | 0.100 |
Why?
| | Point Mutation | 1 | 2014 | 242 | 0.100 |
Why?
| | Disease Progression | 1 | 2021 | 2847 | 0.100 |
Why?
| | Qualitative Research | 3 | 2026 | 1668 | 0.100 |
Why?
| | Proteins | 1 | 2019 | 1016 | 0.090 |
Why?
| | Prospective Studies | 3 | 2022 | 7994 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1569 | 0.090 |
Why?
| | Age Factors | 1 | 2019 | 3329 | 0.090 |
Why?
| | DNA-Binding Proteins | 1 | 2019 | 1484 | 0.090 |
Why?
| | Disease Models, Animal | 2 | 2019 | 4539 | 0.080 |
Why?
| | Pediatrics | 1 | 2018 | 1121 | 0.080 |
Why?
| | Interviews as Topic | 2 | 2026 | 905 | 0.080 |
Why?
| | Research Design | 2 | 2024 | 1129 | 0.070 |
Why?
| | Zebrafish | 2 | 2026 | 532 | 0.070 |
Why?
| | HEK293 Cells | 2 | 2019 | 743 | 0.060 |
Why?
| | Ring Chromosomes | 1 | 2026 | 3 | 0.060 |
Why?
| | Syndrome | 1 | 2026 | 379 | 0.050 |
Why?
| | Chromosome Deletion | 1 | 2024 | 124 | 0.050 |
Why?
| | Sequence Deletion | 1 | 2024 | 191 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 205 | 0.050 |
Why?
| | Failure to Thrive | 1 | 2023 | 28 | 0.050 |
Why?
| | Muscle Hypotonia | 1 | 2023 | 33 | 0.050 |
Why?
| | Rare Diseases | 1 | 2024 | 115 | 0.050 |
Why?
| | Animals | 3 | 2026 | 37948 | 0.050 |
Why?
| | Exons | 1 | 2024 | 362 | 0.050 |
Why?
| | Motor Skills | 1 | 2024 | 104 | 0.050 |
Why?
| | Suggestion | 1 | 2022 | 2 | 0.050 |
Why?
| | Munc18 Proteins | 1 | 2022 | 24 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3887 | 0.040 |
Why?
| | Chromosome Aberrations | 1 | 2022 | 164 | 0.040 |
Why?
| | Patient Acuity | 1 | 2021 | 47 | 0.040 |
Why?
| | Time-to-Treatment | 1 | 2023 | 242 | 0.040 |
Why?
| | Patient-Centered Care | 1 | 2026 | 545 | 0.040 |
Why?
| | Data Interpretation, Statistical | 1 | 2022 | 368 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 480 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 496 | 0.040 |
Why?
| | Cerebral Palsy | 1 | 2022 | 137 | 0.040 |
Why?
| | Proteostasis Deficiencies | 1 | 2019 | 5 | 0.040 |
Why?
| | Vitamin B 6 Deficiency | 1 | 2019 | 6 | 0.040 |
Why?
| | Unfolded Protein Response | 1 | 2019 | 58 | 0.040 |
Why?
| | Vitamin B 6 | 1 | 2019 | 11 | 0.040 |
Why?
| | Pyridoxal Phosphate | 1 | 2019 | 25 | 0.040 |
Why?
| | Pyridoxine | 1 | 2019 | 37 | 0.040 |
Why?
| | Diet, Ketogenic | 1 | 2019 | 38 | 0.040 |
Why?
| | Interdisciplinary Communication | 1 | 2020 | 200 | 0.040 |
Why?
| | Corpus Callosum | 1 | 2019 | 72 | 0.040 |
Why?
| | Mutation, Missense | 1 | 2020 | 338 | 0.040 |
Why?
| | Consensus | 1 | 2020 | 475 | 0.040 |
Why?
| | White Matter | 1 | 2020 | 153 | 0.030 |
Why?
| | Protein Transport | 1 | 2019 | 437 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2020 | 605 | 0.030 |
Why?
| | Middle Aged | 3 | 2026 | 35968 | 0.030 |
Why?
| | Prevalence | 1 | 2024 | 2839 | 0.030 |
Why?
| | Autism Spectrum Disorder | 1 | 2022 | 410 | 0.030 |
Why?
| | Emotions | 1 | 2022 | 578 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2019 | 217 | 0.030 |
Why?
| | Alternative Splicing | 1 | 2019 | 247 | 0.030 |
Why?
| | Advisory Committees | 1 | 2018 | 228 | 0.030 |
Why?
| | Alleles | 1 | 2019 | 886 | 0.030 |
Why?
| | Protein Conformation | 1 | 2019 | 935 | 0.030 |
Why?
| | Genotype | 1 | 2020 | 1847 | 0.030 |
Why?
| | Down Syndrome | 1 | 2022 | 522 | 0.030 |
Why?
| | United States | 2 | 2024 | 16018 | 0.030 |
Why?
| | Organ Size | 1 | 2014 | 461 | 0.030 |
Why?
| | Models, Molecular | 1 | 2019 | 1610 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 1995 | 0.020 |
Why?
| | Logistic Models | 1 | 2014 | 2114 | 0.020 |
Why?
| | Aged | 1 | 2022 | 25955 | 0.010 |
Why?
|
|
Demarest's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|